These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 33390268)
21. Which is the best predictor of de novo donor-specific antibodies in a cohort of non-sensitized first kidney transplantation: Antigenic, allelic, epitope, or physiochemical HLA mismatches? Delion A; Girerd S; Duarte K; Girerd N; Schikowski J; Kessler M; Frimat L; Aarnink A Clin Transplant; 2019 Apr; 33(4):e13508. PubMed ID: 30821002 [TBL] [Abstract][Full Text] [Related]
22. Eplet mismatches associated with de novo donor-specific HLA antibody in pediatric kidney transplant recipients. Charnaya O; Jones J; Philogene MC; Chiang PY; Segev DL; Massie AB; Garonzik-Wang J Pediatr Nephrol; 2021 Dec; 36(12):3971-3979. PubMed ID: 34100108 [TBL] [Abstract][Full Text] [Related]
23. HLA class II Eplet mismatch predicts De Novo DSA formation post lung transplant. Walton DC; Cantwell L; Hiho S; Ta J; Wright S; Sullivan LC; Snell GI; Westall GP Transpl Immunol; 2018 Dec; 51():73-75. PubMed ID: 30321645 [TBL] [Abstract][Full Text] [Related]
24. The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients. Sharma A; Taverniti A; Graf N; Teixeira-Pinto A; Lewis JR; Lim WH; Alexander SI; Durkan A; Craig JC; Wong G Pediatr Nephrol; 2020 Jun; 35(6):1061-1068. PubMed ID: 32065279 [TBL] [Abstract][Full Text] [Related]
25. Predictive value of molecular matching tools for the development of donor specific HLA-antibodies in patients undergoing lung transplantation. Kleid L; Walter J; Vorstandlechner M; Schneider CP; Michel S; Kneidinger N; Irlbeck M; Wichmann C; Möhnle P; Humpe A; Kauke T; Dick A HLA; 2023 Sep; 102(3):331-342. PubMed ID: 37068792 [TBL] [Abstract][Full Text] [Related]
26. Racial differences in incident de novo donor-specific anti-HLA antibody among primary renal allograft recipients: results from a single center cohort study. Everly MJ; Briley KP; Haisch CE; Dieplinger G; Bolin P; Kendrick SA; Morgan C; Maldonado AQ; Rebellato LM Transpl Int; 2017 Jun; 30(6):566-578. PubMed ID: 28211192 [TBL] [Abstract][Full Text] [Related]
27. The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies. Parajuli S; Aziz F; Blazel J; Muth BL; Garg N; Mohamed M; Rice J; Mezrich JD; Hidalgo LG; Mandelbrot D Transplantation; 2021 Jul; 105(7):1548-1555. PubMed ID: 32732618 [TBL] [Abstract][Full Text] [Related]
29. The clinical significance of epitope mismatch load in kidney transplantation: A multicentre study. Daniëls L; Naesens M; Bosmans JL; Abramowicz D; Nagler E; Van Laecke S; Peeters P; Kuypers D; Emonds MP Transpl Immunol; 2018 Oct; 50():55-59. PubMed ID: 29908316 [TBL] [Abstract][Full Text] [Related]
30. Identification of risk epitope mismatches associated with de novo donor-specific HLA antibody development in cardiothoracic transplantation. McCaughan JA; Battle RK; Singh SKS; Tikkanen JM; Moayedi Y; Ross HJ; Singer LG; Keshavjee S; Tinckam KJ Am J Transplant; 2018 Dec; 18(12):2924-2933. PubMed ID: 29847022 [TBL] [Abstract][Full Text] [Related]
31. Terasaki Epitope Mismatch Burden Predicts the Development of De Novo DQ Donor-Specific Antibodies and are Associated With Adverse Allograft Outcomes. Willicombe M; Blow M; Santos-Nunez E; Freeman C; Brookes P; Taube D Transplantation; 2018 Jan; 102(1):127-134. PubMed ID: 28731902 [TBL] [Abstract][Full Text] [Related]
32. Class II HLA Eplet Mismatch Is a Risk Factor for De Novo Donor-Specific Antibody Development and Antibody-mediated Rejection in Kidney Transplantation Recipients. Kishikawa H; Kinoshita T; Hashimoto M; Fukae S; Taniguchi A; Yamanaka K; Nakagawa M; Nishimura K Transplant Proc; 2018 Oct; 50(8):2388-2391. PubMed ID: 30316363 [TBL] [Abstract][Full Text] [Related]
33. Immunologic risk stratification of pediatric heart transplant patients by combining HLAMatchmaker and PIRCHE-II. Mangiola M; Ellison MA; Marrari M; Bentlejewski C; Sadowski J; Zern D; Niemann M; Feingold B; Webber SA; Zeevi A; J Heart Lung Transplant; 2022 Jul; 41(7):952-960. PubMed ID: 35437211 [TBL] [Abstract][Full Text] [Related]
35. Epitope analysis of HLA-DQ antigens: what does the antibody see? Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284 [TBL] [Abstract][Full Text] [Related]
36. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation. Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305 [TBL] [Abstract][Full Text] [Related]
37. Degree of HLA class II eplet mismatch load improves prediction of antibody-mediated rejection in living donor kidney transplantation. Tafulo S; Malheiro J; Santos S; Dias L; Almeida M; Martins S; Pedroso S; Mendes C; Lobato L; Castro-Henriques A Hum Immunol; 2019 Dec; 80(12):966-975. PubMed ID: 31604581 [TBL] [Abstract][Full Text] [Related]
38. Association of Predicted HLA T-Cell Epitope Targets and T-Cell-Mediated Rejection After Kidney Transplantation. Senev A; Van Loon E; Lerut E; Coemans M; Callemeyn J; Daniëls L; Kerkhofs J; Koshy P; Kuypers D; Lamarthée B; Sprangers B; Tinel C; Van Craenenbroeck AH; Van Sandt V; Emonds MP; Naesens M Am J Kidney Dis; 2022 Dec; 80(6):718-729.e1. PubMed ID: 35690154 [TBL] [Abstract][Full Text] [Related]
39. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861 [TBL] [Abstract][Full Text] [Related]
40. Class II Human Leukocyte Antigen Epitope Mismatch Predicts De Novo Donor-Specific Antibody Formation After Liver Transplantation. Kubal CA; Mangus R; Ekser B; Mihaylov P; Ceballos B; Higgins N; Chalasani N; Ghabril M; Nephew L; Lobashevsky A Liver Transpl; 2018 Aug; 24(8):1101-1108. PubMed ID: 30142248 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]